Roche’s faricimab meets primary endpoint and shows strong durability across two global phase III studies for diabetic macular edema, a leading cause of blindness

Amy Giles
Increasing Engagement

Paul Theisen
Patient Acquisition

Frank Burrell
Scientific Storytelling

Daniel Sontupe
Market Access

David Linetsky
Point-of-Care Marketing

Brenda Snow
Authentic Patient Voice

Pat Purcell
Meeting Engagement

Joey Cohen
Medication Adherence

Suma Ramadas, PhD
Medical Affairs

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Bud Bilanich
Success Coach

Matthew Durham
Omnidynamic Marketing

Matt Turner
Patient Affordability